AKT1 and breast carcinoma: By contrast, treatment of HS578T-Hyg breast cancer cells with the PI3K inhibitor Ly294002 did not alter the cells migratory activity (both control and CCL21 treated cells) (Figure 5A), which is in view with Western Blot studies showing no AKT phosphorylation in CCL21 stimulated HS578T-Hyg cells (Figure 2A).